A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1629-1637

  Britten, Carolyn D ^a   Rowinsky, Eric K ^a   Baker, Sharyn D ^a   Agarwala, Sanjiv S ^b   Eckardt, John R ^a   Barrington, Rebecca ^a   Diab, Sami G ^a   Hammond, Lisa A ^a   Johnson, Tom ^c   Villalona Calero, Miguel ^a   Fraass, Uwe ^d   Statkevich, Paul ^d   Von Hoff, Daniel D ^a   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; ONDANSETRON; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG ELIMINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TONGUE CARCINOMA; UTERUS CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032764491     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavell, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1, d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
2. Tsang, L. L. H., Quarterman, C. P., Gescher, A., and Slack, J. A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol., 27: 342-346, 1991.
3. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., and Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
4. 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res., 5: 309-317, 1999.
5. Reid, J. M., Stevens, D. C., Rubin, D. C., and Ames, M. M. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res., 3: 2393-2398, 1997.
6. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol., 36: 457-462, 1987.
7. 6-alkylguanine-DNA alkyl-transferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer, 67: 1299-1302, 1993.
8. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann. Oncol., 6: 389-393, 1995.
9. 6-benzylguanine: a comparative study in vitro. Br. J. Cancer, 73: 482-490, 1996.
10. 6-alkylguanine-DNA alkyl-transferase activity to temozolomide and BCNU. Br. J. Cancer, 73: 1049-1052, 1996.
11. 6 methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethyl nitrosoureas. Anti-Cancer Drugs, 3: 401-405, 1992.
12. 6-Benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23: 112-116, 1995.
13. 6-Benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1673, 1998.
14. Mizuno, N. S., and Decker, R. W. Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347). Biochem. Pharmacol., 25: 2643-2647, 1976.
15. Wedge, S. R., Porteous, J. K., Glaser, M. G., Marcus, K., and Newlands, E. S. In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs, 8: 92-97, 1997.
16. Pera, M. F., Koberle, B., and Masters, J. R. W. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br. J. Cancer, 71: 904-906, 1995.
17. Raymond, E., Izbicka, E., Soda, H., Gerson, S. L., Dugan, M., and Von Hoff, D. D. Activity of temozolomide against human tumor colony-forming units. Clin. Cancer Res., 3: 1769-1774, 1997.
18. Carter, C. A., Waud, W. R., and Plowman, J. Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc. Am. Assoc. Cancer Res., 35: 297, 1994.
19. Friedman, H. S., Dolan, M. E., Pegg, A. E., Marcelli, S., Deir, S., Catino, J. J., Bigner, D. D., and Schold, S. C. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
20. Plowman, J., Waud, W. R., Koutsoukos, A. D., Rubinstein, L., Moore, T., and Grever, M. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res., 54: 3793-3799, 1994.
21. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., and Gibson, A. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
22. Dhodapkar, M., Rubin, J., Reid, J. M., Burch, P. A., Pitot, H. C., Buckner, J. C., Ames, M., and Suman, V. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin. Cancer Res., 3: 1093-1100, 1997.
23. Eckardt, J. R., Weiss, G. R., Burris, H. A., Rodriguez, G. I., Fields, S. M., Rinaldi, D. A., Drengler, R. L., Dugan, M. H., Batra, V. J., and Von Hoff, D. D. Phase I and pharmacokinetic trial of SCH52365 (temozolomide) given orally daily × 5 days. Proc. Am. Soc. Clin. Oncol., 14: 484, 1995.
24. Brada, M., Moore, S., Judson, I., Batra, V. J., Quartey, P., and Dugan, M. A phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 14: 470, 1995.
25. Brock, C. S., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H., Colquhoun, I., Roddie, M., Glaser, M., Brampton, M. H., and Rustin, G. J. S. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res., 58: 4363-4367, 1998.
26. Bleehan, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J. S., Brampton, M., and Stevens, M. F. G. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
27. O'Reilly, S. M., Newlands, E. S., Glaser, M. G., Brampton, M., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., and Stevens, M. F. G. Temozolomide. A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur. J. Cancer, 29A: 940-942, 1993.
28. Newlands, E. S., O'Reilly, S. M., Glaser, M. G., Bower, M., Evans, H., Brock, C., Brampton, M. H., Colquhoun, I., Lewis, P., Rice-Edwards, J. M., Ilingworth, R. D., and Richards, P. G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer, 32A: 2236-2241, 1996.
29. Levin, V., Yung, A., Prados, M., Poisson, M., Rosenfeld, S., Brada, M., Friedman, H., Albright, R., Olson, J., Bruner, J., Yue, N., Dugan, M., and Temodal Brain Tumor Group. Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma patients. Proc. Am. Soc. Clin. Oncol., 16: 384a, 1997.
30. Al-Sarraf, M., Fletcher, W., Oishi, N., Pugh, R., Hewlett, J. S., Balducci, L., McCracken, J., and Padilla, F. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat. Rep., 66: 31-35, 1982.
31. 6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis (Lond.), 10: 1681-1684, 1989.
32. Piccioni, D., D'Atri, S., Papa, G., Caravita, T., Franchi, A., Bonmassar, E., and Graziani, G. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J. Chemother., 7: 224-228, 1995.
33. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988.
34. Estlin, E. J., Lashford, L., Ablett, S., Price, L., Gowing, R., Gholkar, A., Kohler, J., Lewis, I. J., Morland, B., Pinkerton, C. R., Stevens, M. C. G., Mott, M., Stevens, R., Newell, D. R., Walker, D., Dicks-Mireaux, C., McDowell, H., Reidenberg, R., Statkevich, P., Marco, A., Batra, V., Dugan, M., and Pearson, A. D. J. Phase I study of temozolomide in paediatric patients with advanced cancer. Br. J. Cancer, 78: 652-661, 1998.
35. Gibaldi, M., Perrier, D. Pharmacokinetics, Ed. 2., pp. 409-417. New York, NY: Marcel Dekker, 1982.
36. Lalonde, R. L. Pharmacodynamics. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Ed. 3, pp. 4-1 to 4-33. Vancouver, WA: Applied Therapeutics, 1992.
37. O'Dwyer, P. J., Johnson, S. W., and Hamilton, T. C. Cisplatin and its analogues. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 418-432. New York: Lippincott-Raven Publishers, 1997.
38. 6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol., 51: 1221-1228, 1996.
39. 6-alkyl guanine-DNA-alkyl-transferase activities and sensitivity to alkylating agents in human cancer cell lines. Br. J. Cancer, 73: 861-865, 1996.
40. 6-methylguanine-DNA-methyltransferase activity induced by various treatments in mammalian cells. Cancer Res., 46: 5701-5705, 1986.
41. Friedman, M. A., Kaufman, D. A., Williams, J. E., Resser, K. J., Rosenbaum, E. H., Cohen, R. J., Glassberg, A. B., Blume, M. R., Gershow, J., and Chan, E. Y. C. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group Study. Cancer Treat. Rep., 63: 493-495, 1979.
42. Fletcher, W. S., Green, S., Fletcher, J. R., Dana, B., Jewell, W., and Townsend, R. A. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. Am. J. Clin. Oncol., 11: 589-593, 1988.
43. Fletcher, W. S., Daniels, D. S., Sondak, V. K., Dana, B., Townsend, R., Hynes, H. E., Hutchins, L. F., and Pancoast, J. R. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. Am. J. Clin. Oncol., 16: 359-362, 1993.